Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

Reminder- ZIKV Testing Strategy Webinar Wednesday 8/15/18

Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...

Read More >

National Blood Donor Month

National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >

Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP

TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...

Read More >

New Learning Center with New Content Launches on March 30!

A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...

Read More >

Creative Testing Solutions and Grifols Forge New Testing Partnership

Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...

Read More >